RESEARCH

 

California Institute of Renal Research

The California Institute of Renal Research is a strategic Study Management Organization that collaborates early on cutting edge-therapeutics with Pharma and Device sponsors. Our important role in executing clinical trials that Pioneer New Therapeutics is manifest through Pride in Our GCP Processes and having Passion for the Patients we serve.

History

  • Over two decades of delivering quality GCP studies, including multiple Investigator Initiated Studies (IIS)
  • 500+ studies with nearly 100 sponsors
  • Phase 1B-4 GCP IND, IDE & PMA expertise

Access

  • Direct Access to 150k+ charts in the Balboa Nephrology Medical Group EHR
    ⮕ 40k+ unique patients per year
    ⮕ 4k+ ESRD Patients
    ⮕ Vascular Access Center
  • Additional reach through Sharp & Scripps Healthcare
  • Access to both Fresenius & DaVita Dialysis Centers

Infrastructure

  • 10 Principal Investigators with an average of 11 years research experience
  • 25+ full-time research staff; 12 Research Coordinators with an average tenure of 8 years
  • 6 fully-equipped Research locations in San Diego & Imperial Counties

Principal Investigators

George Fadda, MD, FACP • La Mesa, CA

George Fadda, MD, FACP

  • Research Experience: Founder of California Institute of renal Research (CIRR), 26 years research experience in basic and clinical research. Principal investigator participated in more than 95 phase 2-4 studies. CIRR Research Advisory Committee
  • Publications: More than 50 Articles in Nephrology Journals
  • Research Expertise: All aspects of Kidney disease: Acute renal failure and Chronic Kidney Disease Stages 2-5, ESRD, Type 2 DM, Hypertension, Hyperlipidemia, PCKD, FSGS, IgA Nephropathy, Hyperparathyroidism, Anemia, Iron, Proteinuria, etc.
  • Training: MD – American University Beirut; Fellowship – University of Southern California; Assistant Professor of Medicine / Nephrology University of Southern California

Contact

Jill Meyer, MD | Adam Horeish, MD • Chula Vista, CA

Jill Meyer, MD

  • Research Experience: 20 years
  • Research Expertise: drug device and diagnostics; phase II-IV: CKD 2-5, ESRD, HTN, DMII, hypercholesterolemia, IgA Nephropathy, FSGS, pruritis, anemia, hyperkalemia, vit hyperparathyroidism, infectious disease
  • Training: MD – American University; residency – Hennepin County Medical Center; Fellowship – Emory University

Contact


Adam Horeish, MD

  • Research Experience: 4 years
  • Research Expertise: drug, device, and diagnostics; phase II-IV: CKD 2-5, ESRD, HTN, DMII, hypercholesterolemia, IgA Nephropathy, FSGS, anemia, hyperkalemia, vit hyperparathyroidism, infectious disease
  • Training: MD – Ross University School of Medicine; residency – Western Reserve Care System; Fellowship – University of Vermont

Contact

Arman Faravardeh, MD, FACP, FASN, FAST | Kristian Brown, MD, PhD, FACP • Frost (Transplant & Vascular Access)

Arman Faravardeh, MD, FACP, FASN, FAST

  • Research Experience: 10 years
  • Publications, Lectures & Presentations: over 35
  • Research Expertise: Kidney transplantation including delayed graft function, CMV disease, BK virus, COVID vaccine, APOL1, Belatacept trial, chronic antibody mediated rejection, donor derived cell free DNA assay
  • Training: MD – Medical College of Wisconsin; Residency – Medical College of Wisconsin; Nephrology Fellowship – University of Minnesota; Transplant Nephrology Fellowship – UCLA

Contact


Kristian Brown, MD, PhD, FACP

  • Research Experience: 4 years
  • Research Expertise: drug, device and diagnostics; phase II-IV: surgical transplant, vascular access, CMV, acute rejection, AKI, DGF, infectious disease
  • Training: MD – University of Southern California; PhD in Biomedical Engineering – Wayne State University; residency – Detroit Medical center/Wayne State University; Abdominal Transplant/Hepatobiliary Fellowship – University of Southern California & Children’s Hospital of Los Angeles

Contact

Ramin Berenji, MD, FACP, FASN • El Centro, CA

Ramin Berenji, MD, FACP, FASN

  • Research Experience: 10 years; CIRR Research Advisory Committee
  • Publications: 9 articles/abstracts
  • Research Expertise: drug, device and diagnostics; phase II-IV: CKD 2-5, ESRD, HTN, cad, DMII, AKI, hypercholesterolemia, IgA Nephropathy, pruritis, FSGS, ADPKD, anemia, hyperkalemia, vit d def, hyperparathyroidism, infectious disease
  • Training: MD – University of Hamburg school of medicine; Residency – Good Samaritan Hospital/John Hopkins; Fellowship – Stanford University

Contact

Osman Khawar, MD, MPH | Joseph Hebreo, MD • Escondido, CA

Osman Khawar, MD, MPH

  • Research Experience: 10 years
  • Publications: 15 Articles & 10 Posters
  • Research Expertise: drug, device, diagnostics and investigator sponsored; phase Ia-IV: CKD 2-5, ESRD, HTN, vascular access, home HD, PD, CAD, pruritis, DMII, hypercholesterolemia, IgA Nephropathy, FSGS, anemia, hyperkalemia, hyperparathyroidism
  • Training: MD – Glasgow university; Master’s of Public Health – John Hopkins School of Public health; Residency – St. Mary medical center, Long Beach; fellowship – Harbor-UCLA

Contact


Joseph Hebreo, MD

  • Research Experience: 4 years
  • Publications: 2
  • Research Expertise: drug, device, and diagnostics; phase Ia-IV: CKD 2-5, ESRD, HTN, vascular access, DMII, hypercholesterolemia, IgA Nephropathy, FSGS, anemia, hyperkalemia, hyperparathyroidism
  • Training: MD – Albert Einstein College of Medicine; residency – Naval Medical Center, San Diego; Fellowship – Walter Reed Army Medical Center/National Naval Medical Center

Contact

Dylan Steer, MD | Mark Boiskin, MD • Kearney Mesa, CA

Dylan Steer, MD

  • Research Experience: 15 years
  • Research Expertise: drug, device, diagnostics, and investigator sponsored; phase Ia-IV: CKD 2-5, ESRD, HTN, DMII, pruritis, hypercholesterolemia, anemia, hyperkalemia, hyperparathyroidism
  • Training: MD – Duke University; Residency – Duke University; Fellowship – University of California San Diego.

    Contact


    Mark Boiskin, MD

    • Research Experience: 12 years
    • Research Expertise: drug, device, diagnostics, and investigator sponsored; phase Ia-IV: CKD 2-5, ESRD, HTN, DMII, pruritis, anemia, hyperparathyroidism, dialysis access
    • Training: MD – Stellenbosch medical school (south Africa); Residency – university of Alberta; Fellowship – University of California, San Diego

    Contact

California Institute of Renal Research – La Mesa

California Institute of Renal Research – La Jolla

Phone: 858-558-8150
Fax: 858-346-1024

📍9834 Genesee Ave # 312
La Jolla, CA 92037

California Institute of Renal Research – Kearny Mesa

California Institute of Renal Research – Frost Street

California Institute of Renal Research – Escondido

Phone: 760-294-3162
Fax: 858-366-4745

📍631 E Grand Ave
Escondido, CA 92025

California Institute of Renal Research – El Centro

Phone: 760-337-9575

📍2205 Ross Ave #102
El Centro, CA 92243

California Institute of Renal Research – Chula Vista

Phone: 619-422-2687

📍340 4th Ave #5A
Chula Vista, CA 91910

California Institute of Renal Research – El Centro

Phone: 760-337-9575

📍2205 Ross Ave #102
El Centro, CA 92243

 El Centro

Phone: 760-353-0404
Fax: 760-353-0392

📍2205 Ross Ave #101
El Centro, CA 92243

Selection of Current Studies

Multicenter, Open-Label, Adaptive Design Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RGL4326 Administered via Subcutaneous Injection to Patients with Autosomal Dominant Polycystic Kidney Disease1B
Phase 2 Multicenter, Randomized, Double-Blind, Placebo Controlled, Multiple Dosing Interval, 3-Period Study of the Safety, Tolerability and Effectiveness of adoptively Transferred Viralym-M Multivirus- 2 Specific T Cells in Kidney Transplant Recipients With Either High or Low Levels of BK Viremia2
Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of AZD5718 in Participants with Proteinuric CKD2B
Study to Compare the Efficacy and Safety of Humacyte’s Human Acellular Vessel with that of an Autologous Arteriovenous Fistula in Subjects with ESRD3
A Multicenter, randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients3
Randomized, Double-Blind, Placebo-Controlled Study to assess the Efficacy and Safety of SNF472 When added to Background Care for the Treatment of Calciphylaxis3
A Double-Blind Randomized Placebo-Controlled Parallel Design Multicenter Phase IIIb Study of the effect of Sodium Zirconium Cyclosilicate (SZC) on Serium Potassium and Serium Bicarbonate in Patients with Hyperkalemia and Metabolic Acidosis Associated with CKD3B
Industry Alliance Platform to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients4
A Single-Arm Study to Evaluate the Effectiveness of EndoAVF in a Pre-Dialysis Population4
Translate »